OakChart

Tenaya Therapeutics Inc

TNYAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.3712+0.0006 (0.16%)
2026-11-12 06:30 CET
Market cap
84.61 USD m
Revenue, TTM
3.03 USD m
Net income, TTM
-101.78 USD m
Free cash flow, TTM
-54.65 USD m
EPS diluted, TTM
-0.49
P/E
-
Compare

Price

TNYA against its 20, 50 and 200-day averages
2050200earnings
0.400.600.801.001.209.1M18.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TNYAclose 0.3720-day 0.3850-day 0.52200-day 0.700.3752w low

76.2% under the 52-week high of 1.56 on 12 Nov 2025. 52-week low 0.30 on 5 Nov 2026. Last 15 sessions, 43.0% high to low

Volume 0.36× normal · the line is the 50-bar volume average

Profile

TNYA
52-week range, 6% of the way up
0.301.56

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

Employees70
IPOJul 30, 2021
Beta2.85
ATR, 14d0.04
Rel volume0.36
Short float10.41%
Insider own1.34%
Inst own25.11%

Snapshot

6 groups

Valuation

Index-
Market Cap84.61M
Enterprise Value20.66M
Income-101.78M
Sales3.03M
Book/sh0.24
Cash/sh0.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees70
IPOJul 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S27.92
P/B1.55
P/C1.27
P/FCF-
EV/EBITDA-
EV/Sales6.82
Quick Ratio3.78
Current Ratio3.78
Debt/Eq0.05
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.49
EPS next Y-0.32
EPS next Q-0.09
EPS this Y22.37%
EPS next Y29.69%
EPS next 5Y14.40%
EPS past 3/5Y40.12% 8.63%
Sales past 3/5Y- -
EPS Y/Y TTM38.12%
Sales Y/Y TTM-
EPS Q/Q32.47%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.22.56% 112.12%

Ownership

Insider Own1.34%
Insider Trans-1.22%
Inst Own25.11%
Inst Trans-0.90%
ROA-112.05%
ROE-148.16%
ROIC-185.22%
Gross Margin-87.40%
Oper. Margin-2656.86%
Profit Margin-3356.79%
SMA20-2.66%
SMA50-28.89%
SMA200-46.67%
Trades-

Technical

Shs Outstand227.93M
Shs Float224.88M
Short Float10.41%
Short Ratio8.21
Short Interest23.41M
52W High1.56 -76.21%
52W Low0.30 23.73%
Volatility13.55% 10.43%
ATR (14)0.04
RSI (14)39.64
Beta2.85
Rel Volume0.36
Avg Volume2.85M
Volume1,039,954

Performance

Perf Week0.35%
Perf Month-28.75%
Perf Quarter-49.36%
Perf Half Y-61.31%
Perf YTD-47.83%
Perf Year-73.86%
Perf 3Y-80.04%
Perf 5Y-98.75%
Perf 10Y-
Recom1.00
Target Price3.67
Prev Close0.37
Price0.37
Change %0.16%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Jun 10, 2024InitiatedWWilliam BlairOutperform
Nov 30, 2023InitiatedLLeerink PartnersOutperform$7+1,785.8%
Jun 15, 2022InitiatedHH.C. WainwrightBuy$25+6,634.9%

Peers

Mkt cap
TickerCompanyMkt cap
LXEOLexeo Therapeutics Inc252.01M
RNAAtrium Therapeutics Inc177.32M
RCKTRocket Pharmaceuticals Inc272.24M
SLDBSolid Biosciences Inc848.24M
EWTXEdgewise Therapeutics Inc5.21B
CYTKCytokinetics Inc8.15B
FDMT4D Molecular Therapeutics Inc717.62M
KARDKardigan Inc1.47B
RGNXRegenxbio Inc560.06M
QUREuniQure NV1.72B

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ali FarazChief Executive OfficerAug 17 '26Sale0.7122,23215,778417,782Aug 17 08:50 PM
Tingley WhittemoreChief Medical OfficerAug 17 '26Sale0.717,4245,270214,073Aug 17 08:49 PM
Faraz AliOfficerAug 17 '26Proposed Sale0.7122,23215,778Aug 17 08:46 PM
Whittemore TingleyOfficerAug 17 '26Proposed Sale0.717,4245,270Aug 17 08:45 PM
Ali FarazChief Executive OfficerMay 18 '26Sale0.793,3902,690440,014May 19 07:09 PM
Tingley WhittemoreChief Medical OfficerMay 18 '26Sale0.793,1212,477215,497May 19 07:09 PM
Higa TomohiroSVP, FinanceMay 18 '26Sale0.791,4851,178118,267May 19 07:06 PM
COLUMN GROUP III GP, LP10% OwnerFeb 25 '26Sale0.563,511,8261,975,0510Feb 26 04:23 PM
COLUMN GROUP III GP, LP10% OwnerFeb 24 '26Sale0.62658,440405,1381,649,281Feb 26 04:23 PM
COLUMN GROUP III, LP10% OwnerFeb 25 '26Proposed Sale0.60939,273565,442Feb 25 05:05 PM
COLUMN GROUP III-A, LP10% OwnerFeb 25 '26Proposed Sale0.561,060,727596,553Feb 25 05:04 PM
COLUMN GROUP III GP, LP10% OwnerFeb 20 '26Sale0.61523,734322,0442,102,218Feb 24 04:13 PM
COLUMN GROUP III GP, LP10% OwnerFeb 23 '26Sale0.60306,000182,7431,958,509Feb 24 04:13 PM
COLUMN GROUP III, LP10% OwnerFeb 20 '26Proposed Sale0.621,408,910872,538Feb 20 05:37 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M
AVTMAvantis Total Equity Markets ETFAUM: 758.92M

News

latest 14 of 198
  • Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -14.57%
  • Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +8.27%
  • Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck (Yahoo Finance)
  • Tenaya Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.81% -7.51%
  • Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
  • Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
  • Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer (GlobeNewswire)
  • Tenaya Therapeutics Announces Interim Data from MyPEAK-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms (GlobeNewswire)
  • Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 (GlobeNewswire) -9.20%
  • Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 (GlobeNewswire) +8.77%
  • Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC (GlobeNewswire) -8.31%
  • Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.37%
  • Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.080-0.103-0.1401.700.806
2026Q22026-08-05-0.200-0.068-0.1991.1110.006
2026Q12026-05-06-0.090-0.088-0.0890.237.507
2025Q42026-03-11-0.120-0.121-0.1150.000.008
2025Q32025-11-10-0.120-0.148-0.1240.000.009
2025Q22025-08-06-0.140-0.189-0.1430.000.009
2025Q12025-05-07-0.240-0.190-0.2450.000.009
2024Q42025-03-10-0.280-0.311-0.2760.000.009
2024Q32024-11-06-0.300-0.368-0.2980.000.008
2024Q22024-08-08-0.340-0.392-0.3430.000.009
2024Q12024-05-14-0.400-0.422-0.3980.000.007
2023Q42024-03-18-0.400-0.434-0.4380.000.008
2023Q32023-11-08-0.390-0.473-0.3940.000.007
2023Q22023-08-09-0.450-0.503-0.4530.000.006
2023Q12023-05-10-0.430-0.563-0.4340.000.006
2022Q42023-03-08-0.610-0.632-0.6070.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-4.100-3.820-1.7610.000.00
2022FY-2.760-2.628-2.7590.000.00
2023FY-1.680-1.694-1.6820.000.00
2024FY-1.310-1.351-1.3100.000.00
2025FY-0.590-0.604-1.3100.000.00
2026FY--0.458--5.11
2027FY--0.322--2.48
2028FY--0.370--0.92
2029FY--0.233--35.10
2030FY-0.005--293.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-054112.620.007.20
2026Q4S2026-11-044002.540.007.80
2026Q4S2026-10-204002.540.007.80
2026Q4S2026-09-114202.540.007.80
2026Q4S2026-08-064202.540.007.78
2026Q4S2026-07-303000.000.000.00
2026Q4S2026-05-074000.000.000.00
2026Q4S2026-03-124000.000.000.00
2026Q4S2025-12-122000.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00

Estimate history

EPS, annual-0.635-0.93-1.761-2.759-1.682-1.31-0.592-0.4873
Period2019202020212022202320242025TTM
EPS, quarterly-0.298-0.276-0.245-0.143-0.124-0.115-0.089-0.199-0.084
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000003.03
Period2019202020212022202320242025TTM
Sales, quarterly0000000.2251.111.697
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual41.2841.2841.29166.85768.3386.542216.76227.928
Period2019202020212022202320242025MRQ
Shares, quarterly79.22186.542162.66162.976163.745216.76216.999224.23227.928
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue3.030.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A5.688.448.478.698.714.032.481.99
Gross Profit-2.65-8.44-8.47-8.69-8.71-4.03-2.48-1.99
Selling, General and Administrative Excl. Other77.9184.89107.48122.51116.9168.7836.4325.72
Research and Development61.1168.6186.7498.0494.5454.3931.1023.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-80.56-93.33-115.95-131.19-125.62-72.81-38.91-27.71
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense23.860.000.000.000.000.00-0.07-0.01
Net Income Before Taxes-101.78-90.60-111.13-124.08-123.67-72.72-38.40-26.23
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-101.78-90.60-111.13-124.08-123.67-72.72-38.40-26.23
Net Income From Continuing Operations-101.78-90.60-111.13-124.08-123.67-72.72-38.40-26.23
Net Income-101.78-90.60-111.13-124.08-123.67-72.72-38.40-26.23
EPS (Recurring)-0.38-0.59-1.31-1.68-2.76-1.76-0.93-0.64
EPS (Basic, Before Extraordinaries)-0.49-0.59-1.31-1.68-2.76-1.76-0.93-0.64
EPS (Diluted)-0.49-0.59-1.31-1.68-2.76-1.76-0.93-0.64
EBITDA-74.87-84.89-107.48-122.51-116.91-68.78-36.43-25.72
Non-Operating Income (Expense)2.632.734.827.111.960.090.441.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.3213.0516.5015.3111.472.950.740.41
Price To Sales Ratio44.99-------
Gross Margin-87.40-------
Operating Margin-2,656.86-------
Net Margin-3,356.79-------
Shares Outstanding227.93216.7686.5468.3366.8641.2941.2841.28
Market Capitalization84.6184.61113.29220.68128.62782.28784.34-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.701.110.230.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.391.701.761.831.862.082.662.09
Gross Profit1.30-0.59-1.54-1.83-1.86-2.08-2.66-2.09
Selling, General and Administrative Excl. Other20.1220.3118.5318.9519.0722.0024.8822.56
Research and Development14.8716.6014.8414.8015.3617.3721.0818.69
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.82-20.90-20.07-20.77-20.94-24.08-27.54-24.65
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.6723.190.000.000.000.000.000.00
Net Income Before Taxes-18.94-43.39-19.27-20.18-20.27-23.28-26.86-23.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.94-43.39-19.27-20.18-20.27-23.28-26.86-23.84
Net Income From Continuing Operations-18.94-43.39-19.27-20.18-20.27-23.28-26.86-23.84
Net Income-18.94-43.39-19.27-20.18-20.27-23.28-26.86-23.84
EPS (Recurring)-0.08-0.12-0.09-0.12-0.12-0.14-0.24-0.28
EPS (Basic, Before Extraordinaries)-0.08-0.20-0.09-0.12-0.12-0.14-0.24-0.28
EPS (Diluted)-0.08-0.20-0.09-0.12-0.12-0.14-0.24-0.28
EBITDA-18.42-19.20-18.30-18.95-19.07-22.00-24.88-22.56
Non-Operating Income (Expense)0.550.690.790.600.660.800.670.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.681.702.202.752.933.633.733.76
Price To Sales Ratio44.99120.46667.42-----
Gross Margin76.78-52.97-683.56-----
Operating Margin-1,108.84-1,882.79-8,917.78-----
Net Margin-1,115.97-3,909.28-8,565.33-----
Shares Outstanding227.93224.23217.00216.76163.74162.98162.6686.54
Market Capitalization84.61160.38150.25154.04264.0299.4292.69113.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments100.5561.45104.64186.53251.30128.5326.62
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets5.045.936.947.234.061.431.12
Total Current Assets105.5967.38111.58193.75255.36129.9627.74
Net Property, Plant & Equipment37.0947.7553.2662.7054.7017.189.57
Total Investments and Advances0.420.420.6818.100.550.000.00
Long-Term Note Receivable----0.000.630.48
Deferred Tax Assets2.403.39--2.46--
Other Assets3.834.405.004.393.580.470.28
Total Assets149.32123.33170.51278.94316.65148.2538.09
Short Term Debt Incl. Current Port. of LT Debt3.022.784.324.011.990.000.00
Accounts Payable3.585.165.639.5810.721.020.60
Income Tax Payable0.280.35-----
Other Current Liabilities8.567.6912.7810.669.064.023.52
Total Current Liabilities15.4415.9722.7324.2521.775.044.12
Long Term Debt7.8110.838.1111.0913.710.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities2.403.39--2.46--
Other Liabilities0.410.280.250.230.183.684.58
Total Liabilities26.0530.4831.0935.5738.128.728.70
Non-Equity Reserves0.000.000.000.000.00220.7573.04
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity123.2792.85139.42243.38278.53-81.23-43.65
Total Shareholders Equity123.2792.85139.42243.38278.53-81.23-43.65
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity123.2792.85139.42243.38278.53-81.23-43.65
Total Liabilities & Stockholders Equity149.32123.33170.51278.94316.65148.2538.09
Book Value Per Share0.571.072.043.646.75-1.97-1.06
Tangible Book Value Per Share0.571.072.043.646.75-1.97-1.06
Full-Time Employees709714014110685-
Price to Book Ratio1.551.011.340.422.812.58-
Return on Assets-66.46-75.64-55.21-41.53-31.28-41.21-
Return on Equity-83.84-95.69-64.83-47.39-73.72--
Return on Invested Capital-69.12-107.18-84.11-48.60-24.88--
Quick Ratio6.844.224.917.9911.7325.786.73
Current Ratio6.844.224.917.9911.7325.786.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-101.78-90.60-111.13-124.08-123.67-72.72-38.40-26.23
Depreciation5.688.448.478.698.714.032.481.99
Other Funds (Non Cash)34.6316.3520.0918.9711.383.140.700.40
Funds from Operations-61.46-65.81-82.57-96.42-103.58-65.55-35.21-23.85
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital7.05-2.46-7.93-5.65-0.854.74-0.23-0.25
Cash from Operating Activities-54.41-68.26-90.50-102.07-104.42-60.81-35.45-24.10
Capital Expenditures-0.24-0.62-1.02-1.24-20.63-25.12-9.76-2.93
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.000.000.000.000.000.000.00
Purchase or Sale of Investments0.0056.702.1449.98104.27-213.442.75-2.66
Purchase of Investments0.000.00-87.07-56.64-140.48-213.440.00-12.66
Sale Or Maturity of Investments0.0056.7089.21106.62244.750.002.7510.00
Other Uses0.000.000.00-0.030.000.000.000.00
Other Sources0.000.000.020.000.010.000.000.00
Cash from Investing Activities-0.2156.081.1348.7283.65-238.56-7.01-5.58
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock65.52108.4147.754.5577.77208.88147.2730.51
Repurchase of Common Pref Stock0.000.000.000.000.00-0.01-0.00-0.00
Sale of Common Pref Stock65.52108.4147.754.5577.77208.90147.2730.51
Proceedsfrom Stock Options60.56108.2746.773.8777.39208.52147.2430.45
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.410.000.00-0.500.000.090.000.00
Other Financing Activities Uses-0.410.000.00-0.500.000.000.000.00
Cash from Financing Activities65.11108.4147.754.0577.77208.97147.2730.51
Net Change in Cash10.4896.22-41.62-49.3156.99-90.41104.810.83
Free Cash Flow-54.65-68.88-91.53-103.31-125.05-85.93-45.21-27.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments66.8078.0880.89100.5556.3171.67
Short Term Receivables0.570.3710.630.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.647.555.055.044.934.21
Total Current Assets71.0186.0196.56105.5961.2475.88
Net Property, Plant & Equipment3.615.4634.7237.0939.5041.97
Total Investments and Advances0.420.420.420.420.420.42
Deferred Tax Assets---2.40--
Other Assets1.641.653.373.833.833.89
Total Assets76.6893.54135.07149.32104.98122.15
Short Term Debt Incl. Current Port. of LT Debt2.422.883.123.022.932.83
Accounts Payable3.662.901.913.582.843.30
Income Tax Payable0.040.530.410.280.150.52
Other Current Liabilities12.6812.7111.358.567.296.01
Total Current Liabilities18.8019.0216.7815.4413.2112.65
Long Term Debt0.431.077.007.818.609.38
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.40--
Other Liabilities2.934.045.100.410.300.29
Total Liabilities22.1624.1328.8826.0522.1122.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity54.5269.41106.19123.2782.8799.83
Total Shareholders Equity54.5269.41106.19123.2782.8799.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity54.5269.41106.19123.2782.8799.83
Total Liabilities & Stockholders Equity76.6893.54135.07149.32104.98122.15
Book Value Per Share0.240.310.490.570.510.61
Tangible Book Value Per Share0.240.310.490.570.510.61
Full-Time Employees---70--
Price to Book Ratio1.551.511.221.412.640.83
Return on Assets-112.05-95.61-59.50-66.46-76.77-69.82
Return on Equity-148.16-121.86-73.59-83.84-96.44-85.21
Return on Invested Capital-34.46-61.57-17.03-15.39-22.17-21.32
Quick Ratio3.784.525.756.844.646.00
Current Ratio3.784.525.756.844.646.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-18.94-43.39-19.27-20.18-20.27-23.28
Depreciation0.391.701.761.831.862.08
Other Funds (Non Cash)2.9325.332.863.523.734.58
Funds from Operations-15.62-16.36-14.65-14.83-14.68-16.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.0712.81-4.580.89-0.921.01
Cash from Operating Activities-17.68-3.55-19.23-13.94-15.60-15.61
Capital Expenditures0.00-0.16-0.01-0.07-0.03-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.008.8925.13
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.008.8925.13
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.03-0.16-0.01-0.078.8624.99
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.370.910.0058.240.38-0.48
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.370.910.0058.240.38-0.48
Proceedsfrom Stock Options2.370.000.0058.200.36-0.55
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.410.000.000.00
Other Financing Activities Uses0.000.00-0.410.000.000.00
Cash from Financing Activities6.370.91-0.4158.240.38-0.48
Net Change in Cash-11.29-2.80-19.6644.23-6.368.90
Free Cash Flow-17.68-3.71-19.25-14.01-15.62-15.76

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.41%23.4M224.9M2.76M
2026-10-1510.18%22.5M221.2M2.58M
2026-09-3010.36%22.9M221.2M2.31M
2026-09-159.78%21.6M221.2M2.13M
2026-08-319.39%20.8M221.3M2.43M
2026-08-149.53%21.1M221.3M2.68M
2026-07-3110.07%22.0M218.3M3.38M
2026-07-1511.80%24.9M211.2M3.70M
2026-06-3012.42%26.2M211.2M3.60M
2026-06-1513.57%28.7M211.2M3.75M
2026-05-2913.87%29.3M211.2M4.61M
2026-05-1513.61%28.8M211.2M4.67M
2026-04-3017.20%27.9M162.3M4.27M
2026-04-1516.12%26.1M161.8M4.42M
2026-03-3112.32%25.2M204.5M4.45M
2026-03-1312.35%25.3M204.5M5.08M
2026-02-2711.54%23.6M204.1M4.93M
2026-02-1312.61%25.7M204.1M4.72M
2026-01-3012.28%24.9M203.2M4.64M
2026-01-1511.54%23.5M203.5M4.66M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.053.66733.000.000.421-0.0040.000
call1.000.000.050.056.2221050.000.321-0.0070.000
call1.500.000.100.007.4530.000.000.288-0.0090.000
call2.000.000.500.008.2180.000.000.281-0.0090.000
call2.500.003.800.009.2650.000.000.273-0.0100.000
call5.000.003.800.0011.0030.000.000.253-0.0110.000
call7.500.003.800.0011.9380.000.000.245-0.0120.000
put0.500.001.000.200.0002.000.00-0.579-0.0050.000
put1.000.351.350.700.0003.001.00-0.679-0.0080.000
put1.500.801.501.200.0004.002.00-0.705-0.0090.000
put2.001.302.301.700.0009.005.00-0.719-0.0090.000
put2.500.804.702.200.00011.001.00-0.727-0.0100.000
put5.004.007.004.700.0009.0011.00-0.747-0.0110.000
put7.505.609.507.200.00011.0010.00-0.755-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-09SEC
2026-10-13PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-09SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-08-24SCHEDULE 13GSEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-143Initial statement of beneficial ownership of securities2026-07-13SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-13SEC
2026-07-028-KCurrent report2026-06-29SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-298-KCurrent report2026-05-27SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080021.05K2
2026-070000
2026-060000
2026-05006.34K3
2026-040000
2026-030000
2026-02005.94M9
2026-010000
2025-120000
2025-11009.80K3

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.27%
MILLENNIUM MANAGEMENT LLC2.96%
CITADEL ADVISORS LLC2.10%
RENAISSANCE TECHNOLOGIES LLC1.97%
BlackRock, Inc.1.85%
Empery Asset Management, LP1.78%
MARSHALL WACE, LLP1.61%
GSA CAPITAL PARTNERS LLP1.23%
GEODE CAPITAL MANAGEMENT, LLC0.98%
Burkehill Global Management, LP0.92%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.37%
VANGUARD EXTENDED MARKET INDEX FUND0.82%
iShares Biotechnology ETF0.69%
Fidelity Extended Market Index Fund0.25%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.10%
Invesco RAFI US 1500 Small-Mid ETF0.10%
Goldman Sachs Absolute Return Tracker Fund0.09%
Ultra-Small Company Market Fund0.08%
Fidelity Nasdaq Composite Index Fund0.06%

OakChart. TNYA. Cached 15 minutes.